Stock 600518 KANGMEI PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

All News Kangmei Pharmaceutical Co., Ltd.

Equities

600518

CNE0000017M1

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-05-30 pm EDT 		5-day change 1st Jan Change
1.85 CNY -0.54% Intraday chart for Kangmei Pharmaceutical Co., Ltd. -3.14% -0.54%
Apr. 30 Kangmei Pharmaceutical Logs Profit in Q1 MT
Apr. 29 Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Kangmei Pharmaceutical Logs Profit in Q1
MT
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Kangmei Pharmaceutical Returns to Profit in 2023; Shares Decline 4%
MT
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Court Dismisses Winding-Up Petition Against Kangmei Pharma's Unit
MT
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
CI
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
CI
China’s Securities Regulator Fines 37 Brokerages Since H1 2019
MT
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
Former Kangmei Chairman Loses Appeal Against 12-Year Sentence
MT
Kangmei Pharmaceutical Co., Ltd. announced that it has received CNY 6.5 billion in funding from Guangdong Shennong Enterprise Management Partnership (Limited Partnership), GF Securities Co., Ltd., Investment Arm, Wuhu Xintongrui Enterprise Management Center (Limited Partnership), Shenzhen Zhaoping Linghang Investment Center (Limited Partnership), China Resources Shenzhen International Investment Trust Co., Ltd.
CI
Kangmei Pharmaceutical Co., Ltd. announced that it expects to receive CNY 6.5 billion in funding from Guangdong Shennong Enterprise Management Partnership (Limited Partnership), GF Securities Co., Ltd., Investment Arm, Wuhu Xintongrui Enterprise Management Center (Limited Partnership), Shenzhen Zhaoping Linghang Investment Center (Limited Partnership), China Resources Shenzhen International Investment Trust Co., Ltd.
CI
Kangmei Fraud Case Decision Triggers Exodus of Independent Directors From Listed Firms
MT
Kangmei to Get $1 Billion Government-Led Bailout
MT
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021
CI
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 600518 Stock
  4. News Kangmei Pharmaceutical Co., Ltd.